Investors

2015 News

Keyword Search
 
2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
Jun 15, 2015Tosedostat In Combination With Low Dose Cytarabine Achieves Primary Endpoint In Phase 2 Study In Elderly Patients With AML
Responders Achieve 45 Percent Complete Remission Rate, Nearly Double the Upper Limit of Expected Results; 55 Percent of Responding Patients Remain in Remission for a Median of 319 Days Data Presented at the 20th Congress of the European Hematology Association, June 11-14, 2015 VIENNA, June 15, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced findings from an investigator-sponsored Phase 2 trial in patients with either primary (de novo) acute... 
Printer Friendly Version
Jun 12, 2015Pacritinib Phase 3 Study Shows Positive Results In Patient Reported Outcomes Measuring Quality Of Life In Patients With Myelofibrosis
Significant Improvements in Symptom Score were Reported with Pacritinib, Across All Measured Symptoms, Compared to Best Available Therapy VIENNA, June 12, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxter International's BioScience business (NYSE: BAX) today announced new patient-reported outcome (PRO) data for pacritinib – an investigational oral multikinase inhibitor with specificity for JAK2 and FLT3 – from the Phase 3 PERSIST-1 study. As recently... 
Printer Friendly Version
Jun 10, 2015CTI BioPharma And Baxter Announce Patient-Reported Outcomes (PROs) From Pacritinib Phase 3 In Patients With Myelofibrosis To Be Presented In Late-Breaking Session At EHA
Pacritinib PROs Abstract (#LB2072) also to be Highlighted in the Official EHA Press Program SEATTLE and DEERFIELD, Ill., June 10, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxter International's BioScience business (NYSE:BAX) today announced that Patient Reported Outcomes (PROs) data from the Phase 3 PERSIST-1 trial, evaluating pacritinib in patients with myelofibrosis, will be highlighted in a late-breaking oral presentation at the upcoming 20th Co... 
Printer Friendly Version
Jun 10, 2015CTI BioPharma Amends Loan Agreement
SEATTLE, June 10, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today announced that it has amended its existing loan agreement with Hercules Technology Growth Capital, Inc. (Hercules). Pursuant to the amendment, Hercules agreed to provide term loans in an aggregate principal amount of up to $25.0 million under the facility, inclusive of amounts outstanding immediately prior to closing of the amendment.  On June 9, 2015, approximately $6.2 million (less fees and expenses) was f... 
Printer Friendly Version
May 30, 2015Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
Study demonstrates improvement in key disease measurements and disease-related symptoms with pacritinib treatment compared to best available therapy, regardless of platelet levels at the time of enrollment Treatment resulted in improvements in severe thrombocytopenia and severe anemia, eliminating the need for blood transfusions in a quarter of patients who were transfusion dependent at the time of enrollment CHICAGO, May 30, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASD... 
Printer Friendly Version
May 06, 2015CTI BioPharma Reports First Quarter 2015 Financial Results
- Late-breaking Abstract for Pacritinib Accepted for Presentation at ASCO - - Conference Call Scheduled for Today at 4:30 p.m. Eastern Time - SEATTLE, May 6, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today reported financial results for the first quarter ended March 31, 2015. "After reporting positive top-line results from the PERSIST-1 Phase 3 clinical trial of pacritinib during the quarter, we have subsequently received positive feedback from a number of treat... 
Printer Friendly Version
Apr 23, 2015CTI BioPharma to Report First Quarter 2015 Financial Results on May 6, 2015
SEATTLE, April 23, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today that it plans to report its first quarter 2015 financial results on Wednesday, May 6, 2015, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT). Access to the event can be obtained as follows: Wednesday, May 6 1:... 
Printer Friendly Version
Apr 22, 2015CTI BioPharma and Baxter Announce Phase 3 Data of Pacritinib in Patients with Myelofibrosis to be Presented in Late-Breaking Session at ASCO
-- Pacritinib Abstract #LBA7006 also to be Highlighted in the Official ASCO Press Program -- SEATTLE and DEERFIELD, Ill., April 22, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxter International Inc. (NYSE:BAX) today announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis will be highlighted in a late-breaking oral presentation at the upcoming American Society of ... 
Printer Friendly Version
Mar 16, 2015CTI BioPharma Announces Publication In Blood Of Phase 2 Results Of Pacritinib In Patients With Myelofibrosis
SEATTLE, March 16, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor currently in Phase 3 development in the PERSIST program. Dr. Rami S. Komrokji, Associate Professor of Oncologic Sciences at the University of South Florida College of Medicine and Clinical Director of ... 
Printer Friendly Version
Mar 12, 2015CTI BioPharma Reports Fourth Quarter And Full Year 2014 Financial Results
- Positive Top-Line Results from PERSIST-1 Phase 3 Study of Pacritinib in Patients with Myelofibrosis - - PIXUVRI Receives Reimbursement in Spain - - Total Revenues for Full Year 2014 Reach $60.1 Million - - Conference Call Scheduled for Today at 4:30 p.m. Eastern Time - SEATTLE, March 12, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2014. "In 2014, we successfully accomp... 
Printer Friendly Version
Mar 09, 2015CTI BioPharma And Baxter Announce Positive Top-Line Results From Phase 3 Persist-1 Trial Of Pacritinib For Patients With Myelofibrosis
Trial Meets Primary Endpoint in Intent-to-Treat Population Oral Pacritinib is the First Agent with Clinical Data Supporting its Use in Treating Patients with Myelofibrosis Irrespective of Their Platelet Count, Including Severe and Life-Threatening Thrombocytopenia (low platelets) CTI BioPharma to Host Conference Call Today at 8:00 am EDT SEATTLE and DEERFIELD, Ill., March 9, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxter International Inc. (... 
Printer Friendly Version
Mar 06, 2015CTI BioPharma to Host Conference Call and Webcast on March 9
SEATTLE, March 6, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today that its management plans to host a conference call and webcast on Monday, March 9 at 8:00 a.m. EDT (5:00 a.m. PDT). Access to the event can be obtained as follows: Monday, March 9 5:00 a.m. PDT/8:00 a.m. EDT/1:00 p.m. CET 1-888-471-3843 (domestic) +1 719-325-2376 (international) To access the live audio webcast or the subsequent archived recording, visit CTI BioPharma's website, www.ctibi... 
Printer Friendly Version
Feb 26, 2015CTI BioPharma to Report Fourth Quarter and Full Year 2014 Financial Results on March 12, 2015
SEATTLE, Feb. 26, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today that it plans to report its fourth quarter and full year 2014 financial results on Thursday, March 12, 2015, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT). Access to the event can be obtained as follows: Thur... 
Printer Friendly Version
Feb 03, 2015CTI BioPharma Announces Independent DMC Recommendation to Continue GOG-0212 Phase 3 Study of OPAXIO™ as Maintenance Therapy in Ovarian Cancer, an NRG Oncology/GOG Study
SEATTLE, Feb. 3, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that the Gynecologic Oncology Group, now part of NRG Oncology, informed CTI BioPharma that an independent Data Monitoring Committee (DMC) recommended continuation of the GOG-0212 Phase 3 clinical study of OPAXIO™ (paclitaxel poliglumex) as maintenance therapy in ovarian cancer with no changes following a second of four planned interim analyses for survival and futility. CTI BioPharma ... 
Printer Friendly Version
Jan 12, 2015CTI BioPharma Appoints Alan K. Burnett, M.D. As Therapeutic Area Lead, Myeloid Diseases
SEATTLE, Jan. 12, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) announced today the appointment of Alan K. Burnett, M.D., to serve as the strategic leader for myeloid development. Dr. Burnett most recently served as Professor and Head of the Department of Haematology in the Institute of Cancer and Genetics at Cardiff University and is highly regarded internationally for his work in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndr... 
Printer Friendly Version
Jan 08, 2015CTI BioPharma Announces 2015 Outlook and Recent Drug Portfolio Progress
SEATTLE, Jan. 8, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced an overview of recent progress for its drug portfolio in addition to several anticipated key objectives for 2015. "We ended a productive 2014 and have entered a promising 2015 stronger and more focused than we have been in recent years," said James A. Bianco, M.D., CTI BioPharma's President and Chief Executive Officer. "In the latter part of 2014, we entered into a global developm... 
Printer Friendly Version